Print

Isis Pharmaceuticals, Inc. (ISIS) Reports Financial Results and Highlights for Second Quarter 2013  
8/6/2013 7:24:27 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CARLSBAD, Calif., Aug. 6, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported a pro forma net operating loss (NOL) of $5.3 million and $799,000 for the three and six months ended June 30, 2013, respectively, compared to pro forma net operating income of $6.2 million and a pro forma NOL of $10.0 million for the three and six months ended June 30, 2012. On a GAAP basis, Isis reported a loss from operations of $7.9 million and $6.3 million for the three and six months ended June 30, 2013, respectively, compared to income from operations of $3.7 million for the three months ended June 30, 2012 and a loss from operations of $14.8 million for the six months ended June 30, 2012.

Hey, check out all the research scientist jobs. Post your resume today!

//-->